Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

NCT02401347 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Advanced Breast Cancer
HER2/Neu Negative
Triple-Negative Breast Cancer

Interventions

DRUG: Talazoparib Tosylate

Sponsor

Melinda Telli

Collaborators

[object Object]
[object Object]